Table 2:

Metrics of rCBV estimation methodsa

MethodRC (RCL–RCU)wCVtSDbSDwSD
A) Normalized rCBV (tumor)
    2 (CTI)1.78 (1.44–2.34)0.310.960.710.64
    3 (GV)1.95 (1.57–2.57)0.251.040.770.70
    6 (NEI)2.07 (1.67–2.73)0.241.571.380.75
    1 (UTI)3.16 (2.55–4.16)0.391.551.051.14
    5 (MSD)3.54 (2.86–4.66)0.561.300.251.28
    4 (PBC)3.93 (3.17–5.18)0.671.851.181.42
B) Standardized rCBV (tumor)
    2 (CTI)3869 (3121–5093)0.18314228141397
    4 (PBC)4020 (3243–5292)0.20304526771451
    3 (GV)4214 (3399–5547)0.17316327731521
    1 (UTI)4261 (3437–5609)0.19295825261538
    5 (MSD)4591 (3703–6043)0.13643762201658
    6 (NEI)5250 (4235–6911)0.16573254101895
  • Note:—ΔR2*(t) indicates methods for which the transverse relaxation time courses are computed from the signal time courses; UTI, integration of ΔR2*(t) with the trapezoid rule; CTI, integration of ΔR2*(t) with the trapezoid rule and correction for T1 and T2 extravasation effects; GV, γ-variate fit to ΔR2*(t); NEI, negative enhancement integral of S(t); MSD, maximum signal drop of S(t); PBC, postbolus baseline (recirculation) correction; RCL, lower RC confidence interval; RCU, upper RC confidence interval; tSD, total SD; bSD, between-subject SD; wSD, within-subject SD.

  • a Shown in A and B are the RC, upper and lower 95% CI for RC, wCV, and SDs (total, between, and within-subject) for nRCBV and sRCBV, respectively, in which methods are sorted in order of greatest repeatability, as determined by the RC for nRCBV or sRCBV.